Search Results - "Fecher, Leslie Anne"

Characterization of patients with metastatic melanoma that relapses following complete metabolic response from anti–PD-1 therapy by Ma, Vincent T, Agrawal, Yash Neeraj, Fecher, Leslie Anne, Lao, Christopher D.

“…9530 Background: Treatment with PD-1 inhibitor-based therapy has significantly improved survival in patients with metastatic melanoma over the past decade…”
Get full text

Increased incidence of immune-mediated myocarditis in advanced skin malignancies treated with immune checkpoint inhibitors in the COVID-19 era by Gradone, Allison, Ma, Vincent T, Fecher, Leslie Anne, Yentz, Sarah Elizabeth, Vasbinder, Alexi, Hayek, Salim S., Lao, Christopher D.

“…2664 Background: Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of advanced stage skin malignancies. Immunotherapy related adverse…”
Get full text

Toxicities with combination BRAF and MEK inhibition in resected stage III melanoma by Warrier, Govind, Homan, Morgan, Lao, Christopher D., Yentz, Sarah Elizabeth, Kraft, Shawna, Fecher, Leslie Anne

“…Abstract only e22086 Background: Patients with stage III melanoma are at high risk for recurrence after resection of the primary lesion. The Combi-AD study…”
Get full text

Survival outcomes associated with fewer combination ipilimumab/nivolumab doses in advanced-stage melanoma by Ma, Vincent T, Sun, Yilun, Sitto, Merna, Waninger, Jessica, Fecher, Leslie Anne, Green, Michael, Lao, Christopher D.

“…Abstract only 9549 Background: Standard combination ipilimumab/nivolumab (I/N) is given as 4 induction doses for advanced stage melanoma. While many patients…”
Get full text

The impact of BRAF mutation status on clinical outcomes with single-agent PD-1 inhibitor versus combination ipilimumab/nivolumab by Ma, Vincent The-Luc, Daignault, Stephanie, Waninger, Jessica, Fecher, Leslie Anne, Green, Michael, Alva, Ajjai Shivaram, Lao, Christopher D.

“…Abstract only 10024 Background: Nearly half of all metastatic melanoma patients possess the BRAF V600 mutation. Several therapies are approved for BRAF mutant…”
Get full text

Incidence of treatment effect and characteristic MRI findings in immunotherapy-treated melanoma patients with brain metastases receiving stereotactic radiosurgery by Sovich, Justin Lin, Srinivasan, Ashok, Kim, Michelle Miran, Heth, Jason, Fecher, Leslie Anne, Lao, Christopher D.

“…Abstract only…”
Get full text

NOTOS: A pivotal study of navtemadlin, a first-in-class mouse double minute 2 inhibitor (MDM2i), in patients (pts) with TP53 wild-type ( TP53 WT ) Merkel cell carcinoma (MCC) for whom anti PD-1/L1 therapy has failed by Wong, Michael K.K., Burgess, Melissa Amber, Chandra, Sunandana, Fecher, Leslie Anne, Gaudy-Marqueste, Caroline, Silk, Ann W., Hanna, Glenn J., Lebbe, Celeste, Quéreux, Gaëlle, Rabinowits, Guilherme, Schadendorf, Dirk, Dutriaux, Caroline, Berking, Carola, Martin Liberal, Juan, Ascierto, Paolo Antonio, Houlihan, Emily, Steinmann, Kim, Chan, Tiffanie, Rothbaum, Wayne P., Kelly, Ciara Marie

“…TPS9600 Background: There are no approved therapies for pts with MCC for whom an anti PD-1/L1 agent has failed. The high rate of non-responsive disease after…”
Get full text

Navtemadlin (KRT-232) activity after failure of anti-PD-1/L1 therapy in patients (pts) with TP53 WT Merkel cell carcinoma (MCC) by Wong, Michael K.K., Burgess, Melissa Amber, Chandra, Sunandana, Schadendorf, Dirk, Silk, Ann W., Olszanski, Anthony J., Grob, Jean-Jacques, Jang, Sekwon, Grewal, Jaspreet Singh, Lewis, Karl D., Fecher, Leslie Anne, Rabinowits, Guilherme, Lebbe, Celeste, Shen, Annalise, Chan, Tiffanie, McGreivy, Jesse S., Rothbaum, Wayne P., Hanna, Glenn J., Kelly, Ciara Marie

“…9506 Background: MCC is a rare, aggressive, neuroendocrine skin cancer with a high risk of recurrence and metastases. A median survival of about 4 mo for pts…”
Get full text

Identifying treatment options for BRAFV600 wild-type metastatic melanoma: A SU2C/MRA genomics-enabled clinical trial by LoRusso, Patricia M, Sekulic, Aleksandar, Sosman, Jeffrey A, Liang, Winnie S, Carpten, John, Craig, David W, Solit, David B, Bryce, Alan H, Kiefer, Jeffrey A, Aldrich, Jessica, Nasser, Sara, Halperin, Rebecca, Byron, Sara A, Pilat, Mary Jo, Boerner, Scott A, Durecki, Diane, Hendricks, William P D, Enriquez, Daniel, Izatt, Tyler, Keats, Jonathan, Legendre, Christophe, Markovic, Svetomir N, Weise, Amy, Naveed, Fatima, Schmidt, Jessica, Basu, Gargi D, Sekar, Shobana, Adkins, Jonathan, Tassone, Erica, Sivaprakasam, Karthigayini, Zismann, Victoria, Calvert, Valerie S, Petricoin, Emanuel F, Fecher, Leslie Anne, Lao, Christopher, Eder, J Paul, Vogelzang, Nicholas J, Perlmutter, Jane, Gorman, Mark, Manica, Barbara, Fox, Lisa, Schork, Nicholas, Zelterman, Daniel, DeVeaux, Michelle, Joseph, Richard W, Cowey, C Lance, Trent, Jeffrey M

“…Although combination BRAF and MEK inhibitors are highly effective for the 40-50% of cutaneous metastatic melanomas harboring BRAFV600 mutations, targeted…”
Get full text

Identifying treatment options for BRAF.sup.V600 wild-type metastatic melanoma: A SU2C/MRA genomics-enabled clinical trial by LoRusso, Patricia M, Sekulic, Aleksandar, Sosman, Jeffrey A, Liang, Winnie S, Carpten, John, Craig, David W, Solit, David B, Bryce, Alan H, Kiefer, Jeffrey A, Aldrich, Jessica, Nasser, Sara, Halperin, Rebecca, Byron, Sara A, Pilat, Mary Jo, Boerner, Scott A, Durecki, Diane, Hendricks, William P. D, Enriquez, Daniel, Izatt, Tyler, Keats, Jonathan, Legendre, Christophe, Markovic, Svetomir N, Weise, Amy, Naveed, Fatima, Schmidt, Jessica, Basu, Gargi D, Sekar, Shobana, Adkins, Jonathan, Tassone, Erica, Sivaprakasam, Karthigayini, Zismann, Victoria, Calvert, Valerie S, Petricoin, Emanuel F, Fecher, Leslie Anne, Lao, Christopher, Eder, J. Paul, Vogelzang, Nicholas J, Perlmutter, Jane, Gorman, Mark, Manica, Barbara, Fox, Lisa, Schork, Nicholas, Zelterman, Daniel, DeVeaux, Michelle, Joseph, Richard W, Cowey, C. Lance, Trent, Jeffrey M

“…Although combination BRAF and MEK inhibitors are highly effective for the 40-50% of cutaneous metastatic melanomas harboring BRAF.sup.V600 mutations, targeted…”
Get full text

ADAM trial: A multicenter, randomized, double-blinded, placebo-controlled, phase 3 trial of adjuvant avelumab (anti-PD-L1 antibody) in merkel cell carcinoma patients with clinically detected lymph node metastases; NCT03271372 by Bhatia, Shailender, Brohl, Andrew Scott, Brownell, Isaac, Chandra, Sunandana, Dakhil, Sumia, Ernstoff, Marc S., Fecher, Leslie Anne, Gooley, Ted, Hanna, Glenn J., Hibbert, Reina, Kelly, Ciara Marie, Kiriluk, Samantha M., Nghiem, Paul, Nguyen, Vivian, Pelz, Nichole, Poisson, Aubrey A., Price, Katharine Andress Rowe, Sondak, Vernon K., Thompson, John A., Tykodi, Scott S.

“…Abstract only…”
Get full text

Pilot Trial of Selecting Molecularly Guided Therapy for Patients with Non-V600 BRAF-Mutant Metastatic Melanoma: Experience of the SU2C/MRA Melanoma Dream Team by LoRusso, Patricia M, Boerner, Scott A, Pilat, Mary Jo, Forman, Karen M, Zuccaro, Clarice Y, Kiefer, Jeffrey A, Liang, Winnie S, Hunsberger, Sally, Redman, Bruce G, Markovic, Svetomir N, Sekulic, Aleksandar, Bryce, Alan H, Joseph, Richard W, Cowey, C Lance, Fecher, Leslie Anne, Sosman, Jeffrey Alan, Chapman, Paul B, Schwartz, Gary K, Craig, David W, Carpten, John D, Trent, Jeffrey M

“…Targeted therapies and immunotherapies have led to significant improvements in the treatment of advanced cancers, including metastatic melanoma. However, new…”
Get full text

Tumor-specific circulating cell-free DNA (cfDNA) BRAF mutations (muts) to predict clinical outcome in patients (pts) treated with the BRAF inhibitor dabrafenib (GSK2118436) by Long, Georgina V., Ascierto, Paolo Antonio, Grob, Jean Jacques, Hamid, Omid, Kefford, Richard, Lebbe, Celeste, Minor, David R., Ribas, Antoni, Schadendorf, Dirk, Fecher, Leslie Anne, Trefzer, Uwe, Arya, Nikita, Gagnon, Robert C., Goodman, Vicki L., Siegfried, Anne, Mazumdar, Jolly, Martin, Anne-Marie

“…Abstract only 8518 Background: Tumor specific cfDNA levels in blood increase with tumor burden and decrease following treatment. cfDNA can harbor muts…”
Get full text